Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters











Publication year range
1.
Rev. méd. Chile ; 151(7)jul. 2023.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1565676

ABSTRACT

Introducción: La densitometría ósea (DO) tiene alta especificidad para el diagnóstico de osteoporosis, pero sensibilidad bajo lo óptimo para estimar el riesgo de fracturas. Éste, se puede calcular por algoritmos de predictores, y se ha propuesto incluir los marcadores óseos (MO), pero la magnitud de su asociación es incierta. El MO recomendado para medir resorción ósea es Beta-Cross Laps (B-CTx), y uno de formación ósea es la osteocalcina. Objetivos: 1) Establecer rangos de B-CTx y N-MID osteocalcina (N-MID) en mujeres posmenopáusicas (MPM), y comparar los niveles entre grupos: 1) Control sano y 2) Con DO alterada. Material y Métodos: Se reclutaron MPM, con DO del último año. Se realizó encuesta de factores de riesgo de fracturas y medición de MO. Se excluyeron MPM con causa secundaria para compromiso del recambio óseo. Resultados: 117 MPM (57 control, 60 DO alterada), 18 % osteoporosis, comparables. Los rangos de B-CTx y N-MID fueron 0,41 ± 0,18 [IC95% 0,37- 0,45] y 22,76 ± 7,73 [IC95% 21,29-24,24] ng/mL. Los niveles promedios de B-CTx y N-MID fueron más altos en grupo con DO alterada (0,46 ± 0,19 y 24,29 ± 8,04 ng/mL). Se encontró correlación moderada entre ambos MO, pero débil con DO alterada. Conclusiones: Se determinaron por primera vez rangos de B-CTx y N-MID en MPM chilenas, corroborando la similitud a otros países. Se encontraron valores discretamente más elevados de MO en grupo DO alterada, probablemente atribuible a causas secundarias no reportadas. Estos MO podrían constituir una herramienta complementaria a la DO y FRAX en la evaluación ósea.


Introduction: Bone densitometry (BD) has high specificity in the osteoporosis diagnosis but suboptimal sensitivity to estimate fracture risk. It was proposed that bone turnover markers (BTM) could be included in the osteoporosis risk algorithm, although the extent of its association is unknown. One recommended BTM to assess bone resorption is Beta-Cross Laps (B-CTx), while a BTM to assess bone formation is osteocalcin. Aims: To establish BCTx and N-MID osteocalcin (N-MID) ranges in postmenopausal women (PM) and compare BTM levels in two groups: control and with abnormal BD. Methods: PM with BD within the last year were recruited. A questionnaire of risk factors for fractures was applied, and BTM was measured. Volunteers with diseases that would affect bone remodeling were excluded. Results: 117 PM (57 control and 60 with abnormal BD) were recruited. 18% had osteoporosis, and the groups were comparable. The ranges for B-CTx and N-MID were 0.41 ± 0.18 [IC95% 0.37-0.45] and 22.76 ± 7.73 [IC95% 21.29-24.24] ng/mL. The mean levels of B-CTx and N-MID were higher in the group with abnormal BD (0.46 ± 0.19 and 24.29 ± 8.04 ng/mL). A moderate correlation between both BTM was found, but it was weak with abnormal BD. Conclusions: B-CTx and N-MID ranges were assessed for the first time in Chilean PM, similar to values found in other countries. Slightly higher values of BTM were found in the group with abnormal BD, which the presence of omitted secondary causes could explain. These BTM could be a complementary tool to BD and FRAX in bone evaluation.

2.
Rev Med Chil ; 151(7): 859-868, 2023 Jul.
Article in Spanish | MEDLINE | ID: mdl-39093175

ABSTRACT

INTRODUCTION: Bone densitometry (BD) has high specificity in the osteoporosis diagnosis but suboptimal sensitivity to estimate fracture risk. It was proposed that bone turnover markers (BTM) could be included in the osteoporosis risk algorithm, although the extent of its association is unknown. One recommended BTM to assess bone resorption is Beta-Cross Laps (B-CTx), while a BTM to assess bone formation is osteocalcin. AIMS: To establish BCTx and N-MID osteocalcin (N-MID) ranges in postmenopausal women (PM) and compare BTM levels in two groups: control and with abnormal BD. METHODS: PM with BD within the last year were recruited. A questionnaire of risk factors for fractures was applied, and BTM was measured. Volunteers with diseases that would affect bone remodeling were excluded. RESULTS: 117 PM (57 control and 60 with abnormal BD) were recruited. 18% had osteoporosis, and the groups were comparable. The ranges for B-CTx and N-MID were 0.41 ± 0.18 [IC95% 0.37-0.45] and 22.76 ± 7.73 [IC95% 21.29-24.24] ng/mL. The mean levels of B-CTx and N-MID were higher in the group with abnormal BD (0.46 ± 0.19 and 24.29 ± 8.04 ng/mL). A moderate correlation between both BTM was found, but it was weak with abnormal BD. CONCLUSIONS: B-CTx and N-MID ranges were assessed for the first time in Chilean PM, similar to values found in other countries. Slightly higher values of BTM were found in the group with abnormal BD, which the presence of omitted secondary causes could explain. These BTM could be a complementary tool to BD and FRAX in bone evaluation.


Subject(s)
Biomarkers , Osteocalcin , Osteoporosis, Postmenopausal , Humans , Female , Middle Aged , Reference Values , Osteocalcin/blood , Chile , Biomarkers/blood , Aged , Bone Density/physiology , Case-Control Studies , Risk Factors , Postmenopause/physiology , Postmenopause/blood , Collagen Type I/blood , Bone Remodeling/physiology , Peptides/blood
3.
Revagog ; 3(3): 104-110, Jul-Sept. 2021.
Article in Spanish | LILACS, LIGCSA | ID: biblio-1344331

ABSTRACT

El climaterio es una etapa fisiológica que permite al médico reconocer tempranamente los riesgos de patologías y la gran oportunidad de revertirlas. Este trabajo examinará la evidencia actual de la terapia hormonal en la prevención primaria de la enfermedad cardiovascular en mujeres, así como la importancia que igualmente tienen la indemnidad de los ovarios, el peso normal, el uso correcto de antibióticos, la preservación de la microbiota intestinal, las dietas antioxidantes, los estilos de vida saludables y el obligatorio abandono del hábito de fumar.


Subject(s)
Humans , Female , Climacteric/physiology , Menopause/physiology , Cardiovascular Diseases/prevention & control , Hormone Replacement Therapy , Heart Disease Risk Factors , Smoking/adverse effects , Andropause/physiology , Estradiol/therapeutic use , Atherosclerosis/prevention & control , Gastrointestinal Microbiome/drug effects , Healthy Lifestyle
4.
Rev. centroam. obstet. ginecol ; 16(2): 51-55, abr.-jun. 2011.
Article in Spanish | LILACS | ID: lil-733809

ABSTRACT

Los niveles hormonales varían durante la perimenopausia, incluso en mujeres con períodos menstruales regulares, que presentan niveles altos de FSH y bajos de estradiol. Los cambios que se inician posteriormente en la menstruación son producidos fundamentalmente por el acortamiento de la fase folicular, en la FSH alcanza valores postmenopáusicos, superiores a 40 mUI/ml, con LH dentro de rangos normales...


Subject(s)
Humans , Estrogen Antagonists , Climacteric/physiology , Menopause , Perimenopause/metabolism
5.
Rev. chil. obstet. ginecol ; 65(2): 107-13, 2000. tab, graf
Article in Spanish | LILACS | ID: lil-269455

ABSTRACT

La menopausia se asocia a un demostrado aumento del riesgo de enfermedad cardiovascular y de osteoporosis, lo que justifica el uso de terapia hormonal de reemplazo. Como ésta se plantea por tiempo prolongado, debe ser efectiva en prevenir las complicaciones y en suprimir el síndrome climatérico. Se estudió la eficacia de la asociación de valerato de estradiol (VE) y acetato de ciproterona (CPA) en la reducción de los síntomas asociados a menopausia. Se analizaron, prospectivamente, 342 mujeres durante 6 meses, consignando la intensidad de sus síntomas y los cambios en peso, presión arterial y parámetros bioquímicos. Las oleadas de calor, así como otros síntomas y signos, disminuyeron en intensidad. No hubo diferencia significativa en la evolución del peso ni de la presión arterial, aunque sí en algunos parámetros del perfil lipídico y hepático. Se concluye que la asociación VE y CPA reduce la intensidad de los síntomas climatéricos en el grupo estudiado


Subject(s)
Humans , Female , Middle Aged , Climacteric/drug effects , Cyproterone/pharmacology , Drug Therapy, Combination , Estradiol/pharmacology , Body Weight/drug effects , Dyspareunia/drug therapy , Hormone Replacement Therapy , Hot Flashes/drug therapy , Menstruation , Blood Pressure , Prospective Studies , Sleep , Treatment Outcome , Urinary Incontinence/drug therapy
6.
Reprod. clim ; 11(3): 115-6, jul.-set. 1996. tab
Article in Portuguese | LILACS | ID: lil-182557
10.
In. González Campos, Oscar. Avances en citología: resúmen del congreso y curso internacional de postgrado. Santiago de Chile, CICEROS, ago. 1992. p.71-7.
Monography in Spanish | LILACS | ID: lil-165043
SELECTION OF CITATIONS
SEARCH DETAIL